Greenville, SC – According to filings with the U.S. Securities and Exchange Commission, Kiyatec is raising $24,613,620.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Matthew Gevaert played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kiyatec

Kiyatec is disrupting cancer care by accurately predicting patient specific response and non response before treatment begins. We utilize the patients own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible – making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to todays and tomorrows therapies.

To learn more about Kiyatec, visit http://kiyatec.com/

Contact:
Matthew Gevaert, Chief Executive Officer
864-502-2013
https://www.linkedin.com/in/mattgevaert/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved